Share：
Share this content in WeChat
X
[Chinese][PDF]75566
• Review •
Research progress of radiomics in evaluation of curative effect of pancreatic cancer
FANG Jie  HUANG Xiaohua  LIU Nian  TANG Lingling  HU Yuntao 

Cite this article as: Fang J, Huang XH, Liu N, et al. Research progress of radiomics in evaluation of curative effect of pancreatic cancer[J]. Chin J Magn Reson Imaging, 2021, 12(10): 105-108. DOI:10.12015/issn.1674-8034.2021.10.027.


[Abstract] At present, the treatment methods for pancreatic cancer are developing rapidly, but accurate evaluation of the therapeutic effect of pancreatic cancer has become one of the difficulties in clinical diagnosis and treatment. Radiomics can extract high-throughput feature information contained in medical images, which can not only quantitatively analyze the heterogeneity of tumor noninvasively, but also reflect the therapeutic effect of patients by analyzing the changes of tumor microenvironment Information. This article reviews the application progress of radiomics in evaluating the efficacy of surgery, radiotherapy, chemotherapy and neoadjuvant therapy for pancreatic cancer.
[Keywords] pancreatic cancer；efficacy evaluation；prognosis；radiomics

FANG Jie1   HUANG Xiaohua1*   LIU Nian1   TANG Lingling1, 2   HU Yuntao1  

1 Department of Radiology, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China

2 Department of Radiology, The Second Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China

Huang XH, E-mail: 15082797553@163.com

Conflicts of interest   None.

ACKNOWLEDGMENTS Science and Technology Plan Project of Sichuan Province (No. 2020088); Sichuan Provincial Health Research Project (No. 19PJ203).
Received  2021-04-22
Accepted  2021-06-03
DOI: 10.12015/issn.1674-8034.2021.10.027
Cite this article as: Fang J, Huang XH, Liu N, et al. Research progress of radiomics in evaluation of curative effect of pancreatic cancer[J]. Chin J Magn Reson Imaging, 2021, 12(10): 105-108. DOI:10.12015/issn.1674-8034.2021.10.027.

[1]
Pourshams A, Sepanlou SG, Ikuta KS, et al. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. The Lancet Gastroenterology & Hepatology, 2019, 4(12): 934-947. DOI: 10.1016/S2468-1253(19)30347-4.
[2]
Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
[3]
Chen WQ, Sun KX, Zheng RS, et al. Cancer incidence and mortality in China, 2014[J]. Chin J Cancer Res, 2018, 30(1): 1-12. DOI: 10.21147/j.issn.1000-9604.2018.01.01.
[4]
Katz MHG, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators[J]. Cancer, 2012, 118(23): 5749-5756. DOI: 10.1002/cncr.27636.
[5]
Hou Z, Ren W, Li SS, et al. Radiomic analysis in contrast-enhanced CT: predict treatment response to chemoradiotherapy in esophageal carcinoma[J]. Oncotarget, 2017, 8(61): 104444-104454. DOI: 10.18632/oncotarget.22304.
[6]
Coroller T P, Grossmann P, Hou Y, et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma[J]. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology, 2015, 114(3): 345-350. DOI: 10.1016/j.radonc.2015.02.015.
[7]
Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis[J]. Eur J Cancer, 2012, 48(4): 441-446. DOI: 10.1016/j.ejca.2011.11.036.
[8]
Gillies RJ, Kinahan PE, Hricak H, et al. Radiomics: Images Are More than Pictures, They Are Data[J]. Radiology, 2016, 278(2): 563-577. DOI: 10.1148/radiol.2015151169.
[9]
Cassinotto C, Chong J, Zogopoulos G, et al. Resectable pancreatic adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting pathology and patient outcomes[Z]. Eur J Cancer, 2017, 90: 152-158. DOI: 10.1016/j.ejrad.2017.02.033.
[10]
Yun G, Kim YH, Lee YJ, et al. Tumor heterogeneity of pancreas head cancer assessed by CT texture analysis: association with survival outcomes after curative resection[J]. Sci Rep, 2018, 8(1): 7226. DOI: 10.1038/s41598-018-25627-x.
[11]
Tang TY, Li X, Zhang Q, et al. Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer[Z]. J Magn Reson Imaging, 2020, 52(1): 231-245. DOI: 10.1002/jmri.27024.
[12]
Choi MH, Lee YJ, Yoon SB, et al. MRI of pancreatic ductal adenocarcinoma: texture analysis of T2-weighted images for predicting long-term outcome[J]. Abdom Radiol (NY), 2019, 44(1): 122-130. DOI: 10.1007/s00261-018-1681-2.
[13]
Kim HS, Kim YJ, Kim KG, et al. Preoperative CT texture features predict prognosis after curative resection in pancreatic cancer[J]. Sci Rep, 2019, 9(1): 17389. DOI: 10.1038/s41598-019-53831-w.
[14]
Attiyeh MA, Chakraborty J, Doussot A, et al. Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis[J]. Ann Surg Oncol, 2018, 25(4): 1034-1042. DOI: 10.1245/s10434-017-6323-3.
[15]
Cozzi L, Comito T, Fogliata A, et al. Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma[J]. PloS one, 2019, 14(1): e210758. DOI: 10.1371/journal.pone.0210758.
[16]
Simpson G, Spieler B, Dogan N, et al. Predictive value of 0.35 T magnetic resonance imaging radiomic features in stereotactic ablative body radiotherapy of pancreatic cancer: A pilot study[J]. Med Phys, 2020, 47(8): 3682-3690. DOI: 10.1002/mp.14200.
[17]
Yue Y, Osipov A, Fraass B, et al. Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients[J]. J Gastrointest Oncol, 2017, 8(1): 127-138. DOI: 10.21037/jgo.2016.12.04.
[18]
Cui Y, Song J, Pollom E, et al. Quantitative Analysis of (18)F-Fluorodeoxyglucose Positron Emission Tomography Identifies Novel Prognostic Imaging Biomarkers in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy[J]. Int J Radiat Oncol Biol Phys, 2016, 96(1): 102-109. DOI: 10.1016/j.ijrobp.2016.04.034.
[19]
Rutter CE, Park HS, Corso CD, et al. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base[J]. Cancer, 2015, 121(23): 4141-4149. DOI: 10.1002/cncr.29652.
[20]
Suss NR, Talamonti MS, Bryan DS, et al. Does adjuvant radiation provide any survival benefit after an R1 resections for pancreatic cancer[J]. Surgery, 2018, 163(5): 1047-1052. DOI: 10.1016/j.surg.2017.09.022.
[21]
Xu W, Liu Y, Lu Z, et al. A new endoscopic ultrasonography image processing method to evaluate the prognosis for pancreatic cancer treated with interstitial brachytherapy[Z]. World J Gastroenterol, 2013, 19(38): 6479-6484. DOI: 10.3748/wjg.v19.i38.6479.
[22]
Pancreatic Cancer Professional Committee of Chinese Anti-Cancer Association. Chinese guideline for comprehensive diagnosis and treatment of pancreatic cancer (2020 Edition)[J]. Chin J Surg, 2020, 59(2):81-100. DOI: 10.3760/cma.j.cn112139-20201113-00794.
[23]
Kaissis G, Ziegelmayer S, Lohöfer F, et al. A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy[J]. Plos one, 2019, 14(10): e218642. DOI: 10.1371/journal.pone.0218642.
[24]
Salinas-Miranda E, Khalvati F, Namdar K, et al. Validation of Prognostic Radiomic Features From Resectable Pancreatic Ductal Adenocarcinoma in Patients With Advanced Disease Undergoing Chemotherapy[J]. Can Assoc Radiol J, 2020, 5: 846537120968782. DOI: 10.1177/0846537120968782.
[25]
Cheng S, Cheng Y, Jin Z, et al. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy[Z]. Eur J Radiol, 2019, 113:188-197. DOI: 10.1016/j.ejrad.2019.02.009.
[26]
Yoo SH, Kang SY, Cheon GJ, et al. Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study[J]. J Nucl Med, 2020, 61(1): 33-39. DOI: 10.2967/jnumed.119.226407.
[27]
Sandrasegaran K, Lin Y, Asare-Sawiri M, et al. CT texture analysis of pancreatic cancer[J]. Eur Radiol, 2019, 29(3): 1067-1073. DOI: 10.1007/s00330-018-5662-1.
[28]
Mori M, Passoni P, Incerti E, et al. Training and validation of a robust PET radiomic-based index to predict distant-relapse-free-survival after radio-chemotherapy for locally advanced pancreatic cancer[J]. Radiother Oncol, 2020, 153: 258-264. DOI: 10.1016/j.radonc.2020.07.003.
[29]
Chen X, Oshima K, Schott D, et al. Assessment of treatment response during chemoradiation therapy for pancreatic cancer based on quantitative radiomic analysis of daily CTs: An exploratory study[J]. PloS one, 2017, 12(6): e178961. DOI: 10.1371/journal.pone.0178961.
[30]
Versteijne E, Suker M, Groothuis K, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase Ⅲ PREOPANC Trial[J]. J Clin Oncol, 2020, 38(16): 1763-1773. DOI: 10.1200/JCO.19.02274.
[31]
Chakraborty J, Langdon-Embry L, Cunanan KM, et al. Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients[J]. PloS one, 2017, 12(12): e188022. DOI: 10.1371/journal.pone.0188022.
[32]
Borhani AA, Dewan R, Furlan A, et al. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma[J]. AJR Am J Roentgenol, 2020, 214(2): 362-369. DOI: 10.2214/AJR.19.21152.
[33]
Nasief H, Zheng C, Schott D, et al. A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer[J]. NPJ Precis Oncol, 2019, 3: 25. DOI: 10.1038/s41698-019-0096-z.
[34]
Kim BR, Kim JH, Ahn SJ, et al. CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis[J]. Eur Radiol, 2019, 29(1): 362-372. DOI: 10.1007/s00330-018-5574-0.
[35]
Ciaravino V, Cardobi N, DE Robertis R, et al. CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy[J]. Anticancer Res, 2018, 38(8): 4889-4895. DOI: 10.21873/anticanres.12803.

PREV Imaging manifestations and research progress of sclerosing adenosis of breast
NEXT Research progress of MRI in differentiating Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn